Page last updated: 2024-12-05

2,6-di-tert-butyl-4-hydroxymethylphenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-di-tert-butyl-4-hydroxymethylphenol, also known as BHT (butylated hydroxytoluene), is a synthetic antioxidant commonly used as a food additive to prevent rancidity. It is a white crystalline solid with a faint phenolic odor. BHT is synthesized by reacting p-cresol with tert-butyl alcohol in the presence of a strong acid catalyst. BHT is effective in preventing oxidation of fats and oils, thereby extending their shelf life. It is also used in cosmetics, rubber products, and pharmaceuticals. BHT's antioxidant properties are due to its ability to donate a hydrogen atom to free radicals, thereby preventing chain reactions that lead to oxidative damage. BHT has been studied extensively for its potential health effects. While generally considered safe at low doses, some studies have raised concerns about its potential endocrine disrupting effects and its contribution to liver toxicity. Despite these concerns, BHT remains a widely used and effective antioxidant in various industries. Research continues to investigate its long-term effects and potential alternative antioxidants.'

2,6-di-tert-butyl-4-hydroxymethylphenol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6929
CHEMBL ID225220
CHEBI ID173703
SCHEMBL ID42656
MeSH IDM0056815

Synonyms (67)

Synonym
2,6-di-tert-butyl-4-hydroxymethyl phenol
2,6-di-tert-butyl-4-hydroxymethyl-phenol
4-hydroxymethyl-2,6-di-tert-butylphenol
CHEBI:173703
2,6-ditert-butyl-4-(hydroxymethyl)phenol
3,5-di-t-butyl-4-hydroxybenzyl alcohol
2,6-bis(1,1-dimethylethyl)-4-(hydroxymethyl)phenol
di-tert-butyl-4-hydroxymethyl phenol
antioxidant 754
4-hydroxymethyl-2,6-di-tertbutylphenol
3,5-bis(1,1-dimethylethyl)-4-hydroxybenzenemethanol
bht alcohol
alpha-hydroxy-2,6-di-tert-butyl-p-cresol
brn 2052291
2,6-di-t-butyl-4-hydroxymethylphenol
ccris 7069
benzyl alcohol, 3,5-di-tert-butyl-4-hydroxy-
einecs 201-815-6
benzenemethanol, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-
nsc 159133
ionox 100 antioxidant
ao 754
ionox 100
88-26-6
benzyl alcohol,5-di-tert-butyl-4-hydroxy-
nsc159133
3,5-di-tert-butyl-4-hydroxybenzyl alcohol
2,6-di-tert-butyl-4-(hydroxymethyl)phenol
benzenemethanol,5-bis(1,1-dimethylethyl)-4-hydroxy-
nsc-159133
2,6-di-tert-butyl-4-hydroxymethylphenol
inchi=1/c15h24o2/c1-14(2,3)11-7-10(9-16)8-12(13(11)17)15(4,5)6/h7-8,16-17h,9h2,1-6h
3,5-di-tert-butyl-4-hydroxybenzyl alcohol, 97%
CHEMBL225220
AKOS000249317
D1480
A842513
NCGC00248772-01
dtxcid70211
tox21_200631
dtxsid7020211 ,
cas-88-26-6
NCGC00258185-01
46nd6gqi48 ,
unii-46nd6gqi48
4-06-00-06080 (beilstein handbook reference)
FT-0614733
2,6-di-tert.butyl-4-hydroxymethylphenol
3,5-ditert.butyl-4-hydroxybenzyl alcohol
4-hydroxymethyl-2,6-di-t-butylphenol
4-hydroxy-3,5-di-tert-butyl-benzyl alcohol
AM808204
SCHEMBL42656
W-100408
benzenemethanol, 4-hydroxy-3,5-di-tert-butyl
mfcd00017254
AS-69598
3,5-di-tert-butyl-4-hydroxybenzyl alcohol, 8ci
3,5-di-tert-butyl-4-hydroxy-benzyl alcohol
benzenemethanol, 4-hydroxy-3,5-di-tert.-butyl
3,5-bis(1,1-dimethylethyl)-4-hydroxy-benzenemethanol
2, 6-di-tert-butyl-4-hydroxymethylphenol
3,5-bis(1,1-dimethylethyl)-4-hydroxybenzenemethanol, 9ci
2, 6-di-tert-butyl-4-(hydroxymethyl)phenol
CS-0204438
Q27258951
3,5-di-tert-butyl-4-hydroxybenzylalcohol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency69.91700.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency50.12310.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency62.31360.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency19.12030.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency31.23080.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency44.48620.000214.376460.0339AID720692
retinoid X nuclear receptor alphaHomo sapiens (human)Potency35.03630.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency55.16910.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency69.91700.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.93150.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency56.00480.001024.504861.6448AID743212
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency62.31360.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency62.838419.739145.978464.9432AID1159509
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency62.31360.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.00870.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency69.91700.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency69.91700.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID282835Cytotoxicity against mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID282834Activity against caspase-mediated apoptosis in mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.78 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]